Suzhou Highfine Biotech Co., Ltd. (SHE:301393)

Market Cap	6.44B +10.4%
Revenue (ttm)	638.98M +28.9%
Net Income	113.30M -18.5%
EPS	1.05 -17.8%
Shares Out	107.18M
PE Ratio	57.15
Forward PE	n/a
Dividend	0.41 (0.67%)
Ex-Dividend Date	May 21, 2026

Volume	5,245,100
Open	65.77
Previous Close	66.57
Day's Range	59.70 - 66.49
52-Week Range	46.69 - 74.68
Beta	0.55
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 25, 2026

About Suzhou Highfine Biotech

Suzhou Highfine Biotech Co., Ltd. manufactures and sells chemicals for pharmaceutical research and development, and API production companies in China. The company’s products include building blocks, protein reagents, protein crosslinkers, liposomes, ionic liquids, protective amino acids, unnatural amino acids, nucleotide reagents, etc. Its products are used in fields of peptide, nucleotide, and pharmaceutical synthesis. Suzhou Highfine Biotech Co., Ltd. was founded in 2003 and is based in Suzhou, China.

• Industry: Pharmaceutical Preparations
• Founded: 2003
• Employees: 678
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301393

Financial Performance

In 2025, Suzhou Highfine Biotech's revenue was 602.26 million, an increase of 33.28% compared to the previous year's 451.87 million. Earnings were 114.65 million, a decrease of -14.47%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 19, 2026

Data Sources Report a data error